The Human Factors Compliance Clock Just Ran Out

Ten days ago, on July 22, FDA's Center for Devices and Radiological Health held a town hall walking industry through its final guidance, Content of Human Factors Information in Medical Device Marketing Submissions. This week, the more consequential date arrives: the guidance takes effect, with FDA pointing to August 1 — a Saturday — as the practical compliance date, following a 60-day window that started when the guidance was announced in the Federal Register on May 29.

Sixty days is a short runway for a document this consequential, and industry said so. Seven organizations, including AdvaMed, filed comments on the 2022 draft this guidance finalizes, and AdvaMed specifically argued a one-year transition would be more workable than 60 days. Other commenters asked for at least six months. FDA finalized the 60-day timeline anyway. CDRH has acknowledged that most manufacturers aren't likely to have fully updated human factors packages ready for submissions filed right at the compliance date — but the clock is running regardless of readiness.

What actually changed

The final guidance replaces a 2016 document that named a limited set of device types requiring human factors engineering (HFE) data in premarket submissions. The new framework is broader and more structured: it introduces defined HF Submission Categories and asks sponsors to select the appropriate one directly within the eSTAR submission template, which FDA has already updated to support that selection. That single change — moving HF category selection into the standard submission template rather than leaving it as a supplementary judgment call — is likely to do more to expand the scope of devices requiring human factors validation than any single line in the guidance text. Even under a nominally risk-based framework, formalizing the category selection tends to surface devices that informally skated by without dedicated HF validation in the past.

For sponsors uncertain which category applies, or whether validation testing will be expected at all, FDA is recommending the Q-Submission (pre-submission) program as the way to resolve that ambiguity before filing rather than after. In practice, that means the safest path for a device with any interface complexity is now to raise the human factors question in a pre-sub conversation months ahead of the actual marketing submission — not to make an internal risk-based call and hope the reviewer agrees during the formal review cycle.

The part worth double-checking now

Because the guidance is a complement to FDA's existing companion document, Applying Human Factors and Usability Engineering to Medical Devices, teams that already have a mature HFE program shouldn't expect a complete overhaul — but they should expect closer scrutiny of exactly how HF Submission Category was determined and documented. Reviewers now have a structured place in the eSTAR template to ask the question, which means they will ask it, even on submissions where a company's internal assessment concluded no dedicated HF validation was warranted.

The practical move this week is straightforward: pull any device submissions currently in preparation for filing in the coming months, confirm which HF Submission Category each one falls into under the new framework, and — for anything genuinely ambiguous — get a pre-submission meeting on the calendar rather than defaulting to the prior draft-guidance interpretation. The FDA has been clear that the 60-day runway wasn't extended despite industry's request. It isn't likely to be forgiving of submissions that assume it was.

Sources: U.S. Food and Drug Administration, Content of Human Factors Information in Medical Device Marketing Submissions (Final Guidance), May 29, 2026; FDA CDRH Town Hall, July 22, 2026; Hyman, Phelps & McNamara, P.C.; Medmarc.